Brief: Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/Napi2b Dual Target Adc, Arr-002
12/10/2026 22:29
BRIEF-Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/Napi2b Dual Target Adc, Arr-002 Oct 12 (Reuters) - ArriVent BioPharma, Inc. AVBP.O:
ARRIVENT ANNOUNCES FIRST PATIENT DOSED WITH NOVEL TETRAVALENT MUC16/NAPI2B DUAL TARGET ADC, ARR-002
Source text: ID:nGNX9ldzGJ
Further company coverage: AVBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ArriVent BioPharma
See all newsBrief: Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/Napi2b Dual Target Adc, Arr-002
US RESEARCH ROUNDUP-Allstate, Caribou Biosciences, Zscaler
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
ArriVent falls after lung cancer drug misses late-stage trial goal